Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Fasting plasma glucose level-based formula for estimating starting daily dose in basal-bolus insulin therapy

Nagao, Mototsugu LU ; Harada, Taro ; Tanimura-Inagaki, Kyoko ; Kobayashi, Shunsuke ; Fukuda, Izumi ; Sugihara, Hitoshi and Oikawa, Shinichi (2023) In Scientific Reports 13. p.1-7
Abstract

There is no standard formula for estimating the starting daily dose (SDD) of basal-bolus insulin therapy (BBT). We aimed to develop a formula for estimating SDD and evaluate its efficacy and safety in patients with type 2 diabetes hospitalized for BBT. In the first study (n = 104), we retrospectively analyzed the relationship between peak daily dose (PDD) during hospitalization and clinical parameters. The PDD was significantly associated with fasting plasma glucose (FPG) (R = 0.449, P < 0.0001) and HbA1c levels (R = 0.384, P < 0.0001) but not body weight, body mass index, body surface area, or serum C-peptide levels. Based on the results, we developed a formula for estimating SDD using FPG levels: SDD (U/day) = 0.08 × FPG... (More)

There is no standard formula for estimating the starting daily dose (SDD) of basal-bolus insulin therapy (BBT). We aimed to develop a formula for estimating SDD and evaluate its efficacy and safety in patients with type 2 diabetes hospitalized for BBT. In the first study (n = 104), we retrospectively analyzed the relationship between peak daily dose (PDD) during hospitalization and clinical parameters. The PDD was significantly associated with fasting plasma glucose (FPG) (R = 0.449, P < 0.0001) and HbA1c levels (R = 0.384, P < 0.0001) but not body weight, body mass index, body surface area, or serum C-peptide levels. Based on the results, we developed a formula for estimating SDD using FPG levels: SDD (U/day) = 0.08 × FPG (mg/dL). In the second study (n = 405), we assessed efficacy and safety of the formula by evaluating the M-value from the daily glucose profile and assessing the frequency of hypoglycemia (blood glucose level < 70 mg/dL). When BBT was initiated using the FPG level-based formula, the M-values decreased from 61.0 ± 52.8 to 12.8 ± 10.8 (P < 0.0001), and hypoglycemia was observed in only 3/405 cases (0.74%) under the SDD. The FPG level-based formula is useful for estimating SDD in BBT and is safe for clinical use.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
keywords
Humans, Blood Glucose/analysis, Diabetes Mellitus, Type 2/drug therapy, Fasting, Glycated Hemoglobin, Hypoglycemia/drug therapy, Hypoglycemic Agents/therapeutic use, Insulin/therapeutic use, Retrospective Studies
in
Scientific Reports
volume
13
article number
1032
pages
1 - 7
publisher
Nature Publishing Group
external identifiers
  • pmid:36658284
  • scopus:85146610753
ISSN
2045-2322
DOI
10.1038/s41598-023-28138-6
language
English
LU publication?
no
additional info
© 2023. The Author(s).
id
efac4715-7918-4906-af62-8c05ac47ec78
date added to LUP
2023-02-16 03:30:31
date last changed
2024-02-18 13:20:34
@article{efac4715-7918-4906-af62-8c05ac47ec78,
  abstract     = {{<p>There is no standard formula for estimating the starting daily dose (SDD) of basal-bolus insulin therapy (BBT). We aimed to develop a formula for estimating SDD and evaluate its efficacy and safety in patients with type 2 diabetes hospitalized for BBT. In the first study (n = 104), we retrospectively analyzed the relationship between peak daily dose (PDD) during hospitalization and clinical parameters. The PDD was significantly associated with fasting plasma glucose (FPG) (R = 0.449, P &lt; 0.0001) and HbA1c levels (R = 0.384, P &lt; 0.0001) but not body weight, body mass index, body surface area, or serum C-peptide levels. Based on the results, we developed a formula for estimating SDD using FPG levels: SDD (U/day) = 0.08 × FPG (mg/dL). In the second study (n = 405), we assessed efficacy and safety of the formula by evaluating the M-value from the daily glucose profile and assessing the frequency of hypoglycemia (blood glucose level &lt; 70 mg/dL). When BBT was initiated using the FPG level-based formula, the M-values decreased from 61.0 ± 52.8 to 12.8 ± 10.8 (P &lt; 0.0001), and hypoglycemia was observed in only 3/405 cases (0.74%) under the SDD. The FPG level-based formula is useful for estimating SDD in BBT and is safe for clinical use.</p>}},
  author       = {{Nagao, Mototsugu and Harada, Taro and Tanimura-Inagaki, Kyoko and Kobayashi, Shunsuke and Fukuda, Izumi and Sugihara, Hitoshi and Oikawa, Shinichi}},
  issn         = {{2045-2322}},
  keywords     = {{Humans; Blood Glucose/analysis; Diabetes Mellitus, Type 2/drug therapy; Fasting; Glycated Hemoglobin; Hypoglycemia/drug therapy; Hypoglycemic Agents/therapeutic use; Insulin/therapeutic use; Retrospective Studies}},
  language     = {{eng}},
  month        = {{01}},
  pages        = {{1--7}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Scientific Reports}},
  title        = {{Fasting plasma glucose level-based formula for estimating starting daily dose in basal-bolus insulin therapy}},
  url          = {{http://dx.doi.org/10.1038/s41598-023-28138-6}},
  doi          = {{10.1038/s41598-023-28138-6}},
  volume       = {{13}},
  year         = {{2023}},
}